Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin

Hypertension

Volumn 63, Issue 5, 2014, Pages

  Lefkou, Eleftheria ^a   Mamopoulos, Apostolos ^a   Fragakis, Nikolaos ^a   Dagklis, Themistoklis ^a   Vosnakis, Christos ^a   Nounopoulos, Efthimios ^a   Rousso, David ^a   Girardi, Guillermina ^b  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PRAVASTATIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD PRESSURE; CASE REPORT; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPERTENSION; LETTER; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD PRESSURE; COMORBIDITY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; TREATMENT OUTCOME;

EID: 84902238995     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03115     Document Type: Letter

References (12)

1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005; 330: 565.
2. Kumasawa K, Ikawa M, Kidoya H., Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N., Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011; 108: 1451-1455.
3. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011; 58: 716-724.
4. Ahmed A, Singh J, Khan Y., Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One. 2010; 5:e13663.
5. Redecha P, Franzke CW, Ruf W, Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008; 118: 3453-3461.
6. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine M.M., Hankins GD, Ahmed MS Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013; 209: 373.e1-373.e5.
7. Zarek J, DeGorter MK, Lubetsky A, Kim R.B., Laskin CA, Berger H, Koren G. The transfer of pravastatin in the dually perfused human placenta. Placenta. 2013; 34: 719-721.
8. Ahmed A. New insights into the etiology of preeclampsia: Identification of key elusive factors for the vascular complications. Thromb Res. 2011; 127(SUPPL. 3):S72-S75.
9. International Clinical Trials Registry Platform. Statins to Ameliorate early onset Pre-eclampsia StAmP. http://apps.who.int/trialsearch/trial.aspx? TrialID=ISRCTN23410175. Accessed December 2013.
10. ISRCTN Register. Statins to Ameliorate early onset Pre-eclampsia. http://www.controlled-trials.com/ISRCTN23410175. Accessed December 2013.
11. Costantine MM, Cleary K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013; 121(2 pt 1): 349-353.
12. Lecarpentier E, Morel O, Fournier T., Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012; 72: 773-788.